This Article Abstract Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Seljeflot, I. Articles by Arnesen, H. Search for Related Content PubMed PubMed Citation Articles by Seljeflot, I. Articles by Arnesen, H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Hazardous Substances DB LOSARTAN POTASSIUM

(Hypertension. 1996;27:1299-1304.)
© 1996 American Heart Association, Inc.

Articles

Effect of Angiotensin II Receptor Blockade on Fibrinolysis During Acute Hyperinsulinemia in Patients With Essential Hypertension

Ingebjørg Seljeflot; Andreas Moan; Sverre Kjeldsen; Endre Sandvik; Harald Arnesen

From the Research Forum (I.S.) and Department of Internal Medicine (A.M., S.K., H.A.), Ullevål University Hospital, and Stovner Health Centre (E.S.), Oslo, Norway.

Correspondence to Ingebjørg Seljeflot, Medical Outpatient Clinic, Department of Medicine, Ullevål University Hospital, N-0407 Oslo, Norway.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract We performed the present study to investigate indirectly the in vivo effects of angiotensin II on fibrinolysis and catecholamines by treatment with losartan, a selective angiotensin II type 1 receptor antagonist. The effects were evaluated in basal conditions as well as in two different models of acute hyperinsulinemia physiologically induced by oral glucose ingestion and by a euglycemic glucose clamp technique. Twenty subjects with moderate hypertension were included in a randomized, double-blind, placebo-controlled crossover study of 4-week treatment periods. Plasma levels of catecholamines, tissue plasminogen activator activity and antigen, and plasminogen activator inhibitor type 1 activity and antigen were unchanged in the basal state after 4 weeks of treatment. During both models of hyperinsulinemia, plasminogen activator inhibitor activity and antigen decreased significantly (both P<.001), and tissue plasminogen activator activity increased significantly (P<.01). Norepinephrine did not change during any of the procedures, whereas epinephrine increased significantly after 3 hours of the oral glucose tolerance test. Changes from baseline did not differ between the treatment and placebo regimens during the hyperinsulinemic procedures with regard to either of the fibrinolytic variables or the catecholamines. In conclusion, we could not demonstrate any effects of 4 weeks of treatment with losartan on plasma levels of fibrinolytic variables or catecholamines either in basal conditions or during acute hyperinsulinemia. However, the present findings do not preclude more direct effects of angiotensin II or involvement of other receptor subtypes on fibrinolysis.

Key Words: angiotensin II • fibrinolysis • insulin • catecholamines • hyperinsulinism

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
The fibrinolytic capacity of circulating blood is the result of a dynamic balance between plasminogen activators and inhibitors. TPA and PAI-1 are probably the most important regulators of the system. Decreased fibrinolysis, mainly expressed as elevated PAI-1 levels, has been reported in patients with cardiovascular disease,^{1 2} hypertension,³ and hyperinsulinemia^{3 4 5} as well as in patients with deep-vein thrombosis.⁶

The mechanisms regulating the different components in the fibrinolytic system are still not clarified. Insulin has been suggested as one of the regulators of PAI-1 on the basis of cell culture experiments^{7 8 9} and results from clinical studies showing strong correlations between plasma levels of PAI-1 and insulin^{3 4 5} and insulin resistance.¹⁰ However, several studies examining the effect of an acute increase in blood insulin level with the use of a glucose clamp technique or OGTT have not confirmed insulin per se as a stimulator of PAI-1 release.^{11 12 13} But under these circumstances, several different physiological reactions are involved, including vasodilation and vasoconstriction. As stimulating effects of some vasoactive hormones on TPA release from the endothelium are well established,¹⁴ this could confer a link between insulin and fibrinolysis in acute situations.

An increase in norepinephrine has been demonstrated during both the glucose clamp procedure¹⁵ and oral glucose loading,^{16 17} and results from several studies clearly show that catecholamines (norepinephrine and epinephrine) are involved in the regulation of fibrinolysis, mostly by a stimulating effect on TPA secretion from the vasculature.^{18 19 20}

Some in vitro data have suggested that Ang II, a potent vasoconstrictor, is involved in the mechanisms of fibrinolytic regulation by synthesis of both TPA and PAI-1,²¹ and clinical use of angiotensin-converting enzyme inhibitors has been associated with a reduction in plasma levels of PAI-1.²² Furthermore, Ang II may be a mediator of catecholamine secretion, especially norepinephrine, as the level of circulating norepinephrine has been reported to be decreased in patients treated with Ang II receptor blockers.²³ The expected increase in norepinephrine during hyperinsulinemia thus might be suppressed during treatment with Ang II receptor antagonists.

We are pursuing the hypothesis that Ang II could be a mediator of TPA as well as of norepinephrine release. We have previously demonstrated decreased levels of PAI-1 and increased levels of TPA during an OGTT,¹³ and the same profiles have been shown during glucose clamp procedures,^{12 24} both of which lead to acute hyperinsulinemic states. Ang II receptor antagonism could affect these fibrinolytic reactions and thereby act prothrombotically, either directly by a reduced effect of Ang II or by a decrease in norepinephrine, both possible stimulators of TPA secretion.

The aim of the present study was to investigate the effects of selective Ang II receptor blockade on fibrinolysis and some relevant hormones in the basal situation and two different models of acute hyperinsulinemia: OGTT and euglycemic glucose clamp.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Study Design
A randomized, double-blind, placebo-controlled crossover study with two 4-week periods without washout between periods was performed, including Ang II receptor blockade (losartan) or placebo. The losartan or placebo dose was increased from 50 to 100 mg (one to two tablets) after 2 weeks if diastolic pressure exceeded 90 mm Hg.

Subjects
Twenty subjects (7 women and 13 men; mean age, 48 years; range, 24 to 79) with essential hypertension (blood pressure >140/95 mm Hg and self-assessed home diastolic pressure >90 mm Hg) were recruited from general practice physicians. Seventeen subjects were previously untreated for their hypertension, and 3 had been without medication the previous 3 to 7 weeks. The study was approved by the Regional Ethics Committee, and all participants gave their written, informed consent.

Procedures
All subjects underwent the OGTT 3 to 4 days before the glucose clamp. The same protocol was used after 4 weeks of treatment. All procedures were started with subjects in a fasting state between 8 and 9 AM.

OGTT Procedure
The first blood samples were collected from an antecubital vein before the subjects were given 75 g glucose monohydrate in 400 mL of water orally. Venous blood samples then were drawn 1, 2, and 3 hours after intake. The subjects were in a quiet state during the study.

Glucose Clamp Procedure
Before the glucose clamp procedure was started, venous blood was arterialized as follows: On the right arm, an antecubital vein was cannulated with a short polytetrafluoroethylene catheter (Venflon 17G, Viggo AB) and the arm placed in a heating sleeve (Thermal Vascular Dilatator, Swetron AB) with the temperature set to 52°C. This cannula was used for sampling of arterialized venous blood during the procedure. On the left arm, an antecubital vein was cannulated for later infusion of insulin and glucose. The subjects rested in the supine position for 20 minutes before baseline blood collection.

The euglycemic hyperinsulinemic glucose clamp procedure was performed with a modification of the method described by DeFronzo et al²⁵ and previously detailed.²⁶ Insulin was infused at a fixed rate of 1 mU/kg per minute. Blood samples were taken every 5 minutes for determination of blood glucose concentration with Reflolux II (Boehringer Mannheim GmbH). In addition, blood samples were collected at baseline and after 30, 60, 90, and 120 minutes.

The glucose disposal rate (milligrams per kilogram per minute) was calculated from the amount of glucose infused from 100 to 120 minutes, and the mean serum insulin concentration was determined from the two samples obtained during the last 20 minutes.

Blood Sampling Procedures and Laboratory Methods
Serum glucose was determined enzymatically with a glucose dehydrogenase method (Hoffmann–La Roche), and insulin was measured by a radioimmunoassay with a specific antibody (Linco Research Inc) and an intra-assay coefficient of variation less than 9% at all levels.

Citrated plasma (Becton Dickinson Vacutainer tubes containing 0.129 mmol/L trisodium citrate in a 1:10 dilution) was collected and separated within 30 minutes by centrifugation at 2500g for 20 minutes at 4°C for determinations of PAI-1 activity, PAI-1 antigen, and TPA antigen. Acidified plasma for measurement of TPA activity was obtained with Stabilyte tubes (Biopool AB) as described by Rånby et al.²⁷ PAI-1 and TPA activities were measured amidolytically. Enzyme-linked immunosorbent assay methods with a double-antibody technique were used for determinations of PAI-1 (measuring free PAI-1 as well as in complex with TPA) and TPA antigen (measuring free TPA as well as in complex with PAI-1). Commercial kits (Biopool AB) were used (Spectrolyse/pL, Spectrolyse/Fibrin, TintElize PAI-1, and TintElize TPA, respectively). The interassay coefficients of variation were 4.5% for PAI-1 activity, 8.0% for TPA activity, 7.8% for PAI-1 antigen, and 6.5% for TPA antigen. Plasma epinephrine and norepinephrine were determined by the radioenzymatic technique of Peuler and Johnson as previously detailed.²⁸ Interassay coefficients of variation were 10% for both determinations. For all hormones and fibrinolytic parameters, the same procedures for sample preparations were used with both venous blood during the OGTT and arterialized venous blood from the glucose clamp procedure.

Statistics
For group differences during the test period, the Mann-Whitney rank sum test was used. For differences from baseline to various time points, Student's t test for paired data was used. For correlation analysis, the Pearson correlation coefficient was estimated. A two-tailed value of P.05 was considered statistically significant. Data are presented as mean±SE.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Baseline Assessments
Blood pressure after 4 weeks of treatment was significantly reduced with losartan versus placebo (134±4/83±3 versus 146±3/90±3 mm Hg, P<.001 for systolic and P<.03 for diastolic pressure). With subjects in the basal, fasting state, the two regimens did not differ after 4 weeks of treatment with regard to hormones and metabolic or fibrinolytic variables (Table 1, venous blood samples).

View this table: [in this window] [in a new window]   Table 1. Blood Pressure, Hormones, and Metabolic and Fibrinolytic Variables in the Basal State After 4 Weeks of Treatment With Losartan or Placebo

Insulin and Catecholamine Responses
All subjects were good responders to glucose intake in the OGTT. The measured values of insulin 1 hour after intake did not differ between the treatment regimens (910±465 pmol/L during losartan and 833±436 pmol/L during placebo, P=.499). The mean levels of insulin during the last 30 minutes of the clamp procedure were 1011±59 pmol/L during losartan and 927±52 pmol/L during placebo (P=.09), whereas the glucose disposal rate was 6.7±0.6 mg/kg per minute during losartan and 6.2±0.5 mg/kg per minute during placebo (P=.41).

Changes from baseline did not differ between the treatment regimens with regard to catecholamines in either of the test models (Fig 1). Norepinephrine levels did not increase significantly from baseline to various time points during either of the procedures. Norepinephrine showed no changes during the procedures except during the OGTT, when a significant increase after 3 hours appeared with both treatment regimens (Fig 1).

View larger version (23K): [in this window] [in a new window]   Figure 1. Mean values of norepinephrine (noradrenaline in the figure, A) and epinephrine (adrenaline in the figure, B) during OGTT (left) and glucose clamp (right) in both treatment regimens (n=20). Los indicates losartan; Plac, placebo. **P<.01, *P<.05 vs baseline.

Fibrinolytic Response
Table 2 shows the results of the fibrinolytic variables during the OGTT and glucose clamp. The treatment regimens did not differ significantly with regard to changes from baseline to different time points in any of the variables measured (Table 2). Although TPA activity was significantly higher during placebo compared with losartan at 2 hours (P<.05) and a similar difference of borderline significance occurred at 1 hour (P=.072) during the OGTT, the changes from baseline were not significantly different between the two regimens (P=.232 and P=.288, respectively).

View this table: [in this window] [in a new window]   Table 2. Fibrinolytic Variables During Oral Glucose Tolerance Test and Glucose Clamp During Both Treatment Regimens

During the OGTT, PAI-1 activity decreased significantly (P<.001), as did PAI-1 antigen (P<.001), and TPA activity increased significantly (P<.01) after 1 hour with both treatment regimens; these changes were sustained throughout the test period. During the glucose clamp procedure, fibrinolytic variables after 30 minutes did not change, whereas after 1 hour, the same changes as during the OGTT occurred and were sustained throughout the procedure. TPA antigen did not change significantly from baseline during any of the procedures (Fig 2).

View larger version (19K): [in this window] [in a new window]   Figure 2. Mean values of PAI-1 activity (act, A), PAI-1 antigen (ag, B), TPA activity (t-PA in the figure, C), and TPA antigen (D) during OGTT (left) and glucose clamp (right) in both treatment regimens (n=20). Abbreviations as in Fig 1 legend. **P<.001, *P<.01 vs baseline.

The values of PAI-1 activity, PAI-1 antigen, and TPA activity were systematically lower in the arterialized blood samples during the glucose clamp compared with the venous blood samples during the OGTT.

The correlation coefficient between insulin and PAI-1 activity at baseline was .62 (P<.05).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
In the present study, we investigated the effects of hyperinsulinemia on fibrinolysis in subjects with moderate essential hypertension treated with the AT₁ receptor antagonist losartan or placebo. In the crossover design used, the possible influence of interindividual differences was avoided.

Blood pressure was satisfactorily reduced by losartan, without any adverse effects on lipids or other measured metabolic variables. Thus, Ang II receptor antagonism probably was effectively achieved.

We have confirmed previous observations of increased fibrinolytic activity during acute hyperinsulinemia.^{11 12 13 24} Although we did not have any control subjects receiving saline infusion in the present study, the previously published studies^{12 13} have demonstrated that the rapid effects under these conditions cannot be accounted for by diurnal changes.²⁹

To our knowledge, no studies have been published that compare the two models of acute hyperinsulinemia presently used with regard to their effects on fibrinolysis and catecholamines. As we have found that the same profiles in fibrinolytic variables appear in the same subject in the two models, the effects should be related to insulin itself or to other variables similarly changed during the procedures. We have investigated the effects of 4 weeks of blockade of the Ang II receptor with losartan and thereby indirectly the effect of Ang II on fibrinolysis on the basis of the hypothesis that Ang II might be a potential stimulator of TPA²¹ and catecholamines.²³ If this hypothesis were correct, the increase in TPA during the procedures should have been suppressed during losartan treatment. We could not convincingly demonstrate such an effect (Fig 2C, OGTT). Although losartan treatment resulted in significantly lower levels in TPA activity compared with placebo during the OGTT, the differences in changes from baseline between the treatment regimens were not statistically significant.

No differences in PAI-1 levels were encountered either in basal conditions or during the hyperinsulinemic procedures between the treatment regimens. Thus, our findings do not support those of Ridker et al,³⁰ who demonstrated a dose-dependent increase in PAI-1 during Ang II infusion. However, this increase was shown with a very different model.

In endothelial cell cultures exposed to Ang II, an increase in PAI-1 synthesis and release has been demonstrated, suggesting that Ang II promotes increased plasma levels of PAI-1 in humans.³¹ However, there are conflicting results,³² and stimulatory effects of Ang II on the synthesis of both TPA and PAI-1 in cultured aortic smooth muscle cells have also been reported.²¹ In the study of Vaughan et al,³¹ inhibition of AT₁ and AT₂ receptors did not prevent the expression of PAI-1, suggesting that other angiotensin receptor subtypes are involved in the regulation of fibrinolysis. Thus, the endothelial angiotensin receptor is probably not of the AT₁ subtype. This could explain the lack of effect on fibrinolysis in our study by losartan, which is a selective AT₁ receptor antagonist. Although this assumption is strengthened by the recent findings of Kerins et al,³³ entirely different results have also been published.³⁴ Thus, the mechanisms by which the renin-angiotensin system may interact with fibrinolysis are still debatable.

No differences were observed between the two treatment regimens in norepinephrine and epinephrine levels. These results are not necessarily contradictory to those of Moan et al,²³ who found a significant reduction in norepinephrine levels after 4 weeks of treatment with losartan. In that study, the patients had severe hypertension, and they had been treated with other hypertensive drugs until 3 days before entering the study.

Increased norepinephrine levels in acute hyperinsulinemic states have been described in several studies,^{15 16 17 35} but the results are conflicting.^{18 24 36 37} In the present study, norepinephrine did not increase significantly during either of the procedures, and a similar effect occurred with both treatment regimens, suggesting no effect of Ang II on norepinephrine levels during hyperinsulinemic states. Recently, Jern et al²⁰ demonstrated an acute increase of TPA during norepinephrine infusion in humans that could point to norepinephrine as a direct mediator of TPA release in the current situations. However, with regard to the present results, it seems unlikely that norepinephrine has a regulatory role in fibrinolysis in these hyperinsulinemic states. This is in accordance with the findings of Landin et al.²⁴

Epinephrine, a well-known stimulator of fibrinolysis,^{18 19} did not change during either of the procedures until 2 hours. This is in accordance with several other studies^{15 17 24 37} and confirms the suggestion that the increased fibrinolytic activity during acute hyperinsulinemia is probably not due to epinephrine. The increased levels of epinephrine after 3 hours during the OGTT are not readily explainable, but a physiological epinephrine response to the decreased glucose level would be expected at this time.

The reason for the differences in the levels of the basal fibrinolytic variables between venous and arterialized blood is not clear. One explanation could be a longer resting period before baseline sampling in the clamp procedure. In addition, the clamp procedure was performed with subjects in the supine position, whereas the OGTT was undertaken with subjects sitting.

Taken together, these data show that Ang II receptor blockade with losartan for 4 weeks did not affect the circulating levels of fibrinolytic variables either in basal conditions or during acute hyperinsulinemic states. The hypothesis that losartan could act prothrombotically by giving a smaller increase in TPA than expected during acute hyperinsulinemia could not be confirmed. However, more direct effects on fibrinolysis or the involvement of receptor subtypes other than AT₁ cannot be ruled out. The increased fibrinolysis during acute hyperinsulinemia could not be explained by the action of norepinephrine. It seems reasonable to speculate on the vasoactive effects of insulin itself in playing a regulatory role in these situations, since insulin has the potential of vasodilation as well as vasoconstriction.³⁸ The two models of acute hyperinsulinemia showed the same profiles in the measured variables. Thus, both models seem suitable for examinations during acute hyperinsulinemic states.

	Selected Abbreviations and Acronyms

 

Ang II = angiotensin II AT1, AT2 = angiotensin type 1, type 2 OGTT = oral glucose tolerance test PAI-1 = plasminogen activator inhibitor type 1 TPA = tissue plasminogen activator

View this table: [in this window] [in a new window]   Table 2A.

	Acknowledgments

 
This study was supported by a grant-in-aid from Merck, Sharp & Dohme. The authors thank Ruth Amundsen for expert technical assistance with the catecholamine assays.

Received October 18, 1995; first decision December 5, 1995; accepted February 15, 1996.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Paramo JA, Colucci M, Collen D. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. BMJ. 1985;291:573-574.
2. Hamsten A, Wiman B, deFaire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue-type plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563. [Abstract]
3. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med. 1990;227:273-278. [Medline] [Order article via Infotrieve]
4. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism. 1986;35:250-253. [Medline] [Order article via Infotrieve]
5. Landin K, Stigedal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 1990;39:1044-1048. [Medline] [Order article via Infotrieve]
6. Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost. 1987;57:67-72. [Medline] [Order article via Infotrieve]
7. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost. 1988;60:491-494. [Medline] [Order article via Infotrieve]
8. Kooistra T, Bosma PJ, Tons HAM, van den Berg AP, Meyer P, Princen HMG. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost. 1989;62:723-728. [Medline] [Order article via Infotrieve]
9. Schneider DJ, North TK, Sobel BE. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes. 1992;41:890-895. [Abstract]
10. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism. 1993;42:945-949. [Medline] [Order article via Infotrieve]
11. Grant PJ, Kruithof EKO, Felley CP, Feber JP, Bachmann F. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci. 1990;79:513-516. [Medline] [Order article via Infotrieve]
12. Landin K, Tengborn L, Chmielewska J, von Schenck H, Smith U. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost. 1991;65:130-133. [Medline] [Order article via Infotrieve]
13. Seljeflot I, Eritsland E, Torjesen P, Arnesen H. Insulin and PAI-1 levels during oral glucose tolerance test in patients with coronary heart disease. Scand J Clin Lab Invest. 1994;54:241-246. [Medline] [Order article via Infotrieve]
14. Bachmann F, Kruithof EKO. Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Haemost. 1984;10:6-19. [Medline] [Order article via Infotrieve]
15. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic and neural activation and vasodilation in normal humans. J Clin Invest. 1991;87:2246-2252.
16. Berne C, Fagius J, Niklasson F. Sympathetic response to oral carbohydrate administration: evidence from microelectrode nerve recordings. J Clin Invest. 1989;84:1403-1409.
17. Kleinbaum J, Shamoon H. Selective counter regulatory hormone response after oral glucose in men. J Clin Endocrinol Metab. 1982;55:787-790. [Abstract]
18. Larsson PT, Wiman B, Olsson G, Angelin B, Hjemdahl P. Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis. Thromb Haemost. 1990;63:482-487. [Medline] [Order article via Infotrieve]
19. Chandler WL, Veith RC, Fellingham GW, Levy WC, Schwartz RS, Cerqueira MD, Kahn SE, Larson VG, Cain KC, Beard JC, Abrass IB, Stratton JR. Fibrinolytic response during exercise and epinephrine infusion in the same subjects. J Am Coll Cardiol. 1992;19:1412-1420. [Abstract]
20. Jern C, Selin L, Lern S. In vivo release of tissue-type plasminogen activator across the human forearm during mental stress. Thromb Haemost. 1994;72:285-291. [Medline] [Order article via Infotrieve]
21. van Leeuwen RTJ, Amir K, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation. 1994;90:362-368. [Abstract/Free Full Text]
22. Wright RA, Flapan AD, Alberti KGMM, Ludlam CA, Fox KAA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. Am J Coll Cardiol. 1994;24:67-73. [Abstract]
23. Moan A, Risanger T, Eide I, Kjeldsen SE. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Pressure. 1994;3:185-188. [Medline] [Order article via Infotrieve]
24. Landin K, Tengborn L, Smith U. Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinemic, euglycemic clamp in man. Thromb Haemost. 1994;71:783-787.[Medline] [Order article via Infotrieve]
25. DeFronzo R, Tobin J, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223. [Abstract/Free Full Text]
26. Moan A, Nordby G, Os I, Birkeland K, Kjeldsen SE. Relationship between hemorheological factors and insulin sensitivity in healthy young men. Metabolism. 1994;43:4232-4247.
27. Rånby M, Sundell B, Nilsson T. Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost. 1989;62:917-922. [Medline] [Order article via Infotrieve]
28. Kjeldsen SE, Flaaten B, Eide I, Helgeland A, Leren P. Evidence of increased peripheral catecholamine release in patients with long-standing, untreated essential hypertension. Scand J Clin Invest. 1982;42:217-223. [Medline] [Order article via Infotrieve]
29. Kluft C, Jie AFH, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thromb Haemost. 1988;59:329-332. [Medline] [Order article via Infotrieve]
30. Ridker PM, Gaboury CL, Colin PR, Seely E, Williams G, Vaughan D. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 1993;6:1969-1973.
31. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 1995;95:995-1001.
32. Seljeflot I, Arnesen H, Støen R, Lyberg T. Effects of insulin and some vasoconstrictors on the synthesis and release of t-PA and PAI-1 from cultured human umbilical vein endothelial cells. Fibrinolysis. 1995;9:253-257.
33. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest. 1995;96:2515-2520.
34. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest. 1995;95:1353-1362.
35. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L. Effects of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes. 1981;30:219-225. [Medline] [Order article via Infotrieve]
36. Mitrakou A, Mokan M, Bolli G, Veneman T, Jenssen T, Cryer P, Gerich J. Evidence against the hypothesis that hyperinsulinemia increases sympathetic nervous system activity in man. Metabolism. 1992;41:198-200. [Medline] [Order article via Infotrieve]
37. Moan A, Høieggen A, Nordby G, Birkeland K, Eide I, Kjeldsen SE. The glucose clamp procedure activates the sympathetic nervous system even in absence of hyperinsulinemia. J Clin Endocrinol Metab. 1995;80:3151-3154. [Abstract]
38. Feldman RD, Bierbrier GS. Insulin-mediated vasodilation: impairment with increased blood pressure and body mass. Lancet. 1993;342:707-709.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				B. Gojanovic, F. Feihl, L. Liaudet, and B. Waeber Review: Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension Journal of Renin-Angiotensin-Aldosterone System, March 1, 2008; 9(1): 1 - 9. [Abstract] [PDF]

				A. W.J.H. Dielis, M. Smid, H. M.H. Spronk, K. Hamulyak, A. A. Kroon, H. ten Cate, and P. W. de Leeuw The Prothrombotic Paradox of Hypertension: Role of the Renin-Angiotensin and Kallikrein-Kinin Systems Hypertension, December 1, 2005; 46(6): 1236 - 1242. [Abstract] [Full Text] [PDF]

				P. Sawathiparnich, L. J. Murphey, S. Kumar, D. E. Vaughan, and N. J. Brown Effect of Combined AT1 Receptor and Aldosterone Receptor Antagonism on Plasminogen Activator Inhibitor-1 J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3867 - 3873. [Abstract] [Full Text] [PDF]

				N. J. Brown, S. Kumar, C. A. Painter, and D. E. Vaughan ACE Inhibition Versus Angiotensin Type 1 Receptor Antagonism: Differential Effects on PAI-1 Over Time Hypertension, December 1, 2002; 40(6): 859 - 865. [Abstract] [Full Text] [PDF]

				D. C Felmeden and G. Y. Lip The renin-angiotensin-aldosterone system and fibrinolysis Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 240 - 244. [PDF]

				E. Chabielska, T. Matys, I. Kucharewicz, D. Pawlak, R. Rolkowski, and W. Buczko The involvement of AT2-receptor in the antithrombotic effect of losartan in renal hypertensive rats Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 263 - 267. [Abstract] [PDF]

				N. J. Brown, M. Agirbasli, and D. E. Vaughan Comparative Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Antagonism on Plasma Fibrinolytic Balance in Humans Hypertension, August 1, 1999; 34(2): 285 - 290. [Abstract] [Full Text] [PDF]

				M. Cesari and G. P. Rossi Plasminogen Activator Inhibitor Type 1 in Ischemic Cardiomyopathy Arterioscler. Thromb. Vasc. Biol., June 1, 1999; 19(6): 1378 - 1386. [Full Text] [PDF]

				Correction Hypertension, November 1, 1996; 28(5): 919 - 919. [Full Text]

This Article Abstract Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Seljeflot, I. Articles by Arnesen, H. Search for Related Content PubMed PubMed Citation Articles by Seljeflot, I. Articles by Arnesen, H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Hazardous Substances DB LOSARTAN POTASSIUM